-
PSA measurements after surgery or radiation therapy with curative intent include groups of men with a diverse spectrum of prognosis for prostate cancer mortality.
-
Mean serum PSA levels were significantly higher in polycystic ovary syndrome women compared to healthy women.
-
This meta-analysis suggests that rs1058205 polymorphism of KLK3 is a risk factor for PCa development, polymorphism T>C of rs1058205 is associated with decreased susceptibility to PCa particularly in Caucasian population
-
Five single-nucleotide polymorphisms, rs266881 (OR = 2.92, P < 0.0001), rs174776 (OR = 1.91, P < 0.0001), rs266875 (OR = 1.44, P = 0.016), rs35192866 (OR = 4.48, P = 0.025) and rs1810020 (OR = 2.08, P = 0.034) correlated with an increased risk of male infertility. On the other hand, c.206 + 235 T > C, was more freuqent in the control group, showing protective association.
-
In advanced prostate cancer with PSA levels >1000 ng/mL, sufficient PSA-A2M is present in circulation to produce enzymatic activity against circulating small peptide hormones.
-
The aim of the study was to examine treatment patterns/outcomes with abiraterone (abi)/enzalutamide (enza) throughout PSA progression and near the end of life...abiraterone (abi)/enzalutamide are frequently discontinued for PSA progression alone and continued at end of life . The clinical benefit of these practices warrants additional study.
-
The functional role of glycosylation in prostate-specific KLK3 could pave the way to a deeper understanding of their biology and to medical applications.
-
These results shed a light on the genetic background of Benign prostatic hyperplasia and associated lower urinary tract symptoms and its substantial influence on PSA levels.
-
Studies indicate that ghgh level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) could be detected in the blood [Review].
-
Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.
-
Men with mild to no lower urinary tract symptoms (LUTS) but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia
-
PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer.
-
Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 mug/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 mug/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.
-
PSA was the only independent predictor of extensive lymph node invasion and could be an important preoperative factor for stratifying high-risk patients.
-
ue to the biocompatibility, multivalency, stability, and high structural homogeneity, the t-PSA-specific landscape phage demonstrates as a novel specific interface in biosensors.
-
Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed
-
The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits)
-
he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis.
-
The 12-week PSA response rate was 88% (22/25) and 22% (4/18), median time to PSA progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP-naive and post-AAP cohorts, respectively.
-
The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients